Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
127 studies found for:    Immunodeficiency NOT AIDS | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
Immunodeficiency NOT AIDS | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
Condition: Severe Immunodeficiency Diseases
Intervention: Drug: Fludarabine, Busulfan, and Anti-Thymocyte Globulin
2 Not yet recruiting Novel Testing Procedures
Condition: Immunodeficiencies
Intervention:
3 Not yet recruiting IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
Condition: Primary Immunodeficiency
Intervention: Drug: IgHy10
4 Not yet recruiting Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency
Intervention: Biological: TBX-1400
5 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
6 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
7 Recruiting Generalized Neonatal Screening of Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency, Atypical
Intervention: Biological: SCID screening
8 Recruiting Intensive Care Unit and Secondary and Primary Immune Deficiency
Condition: Primary Immune Deficiency Disorder
Intervention: Other: Internal Medicine consultation
9 Recruiting Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndromes
Interventions: Procedure: blood sampling and skin biopsy;   Procedure: blood sampling or mouth swap;   Procedure: blood sampling
10 Not yet recruiting Neonatal Screening of Severe Combined Immunodeficiencies
Conditions: Severe Combined Immunodeficiency;   Neonatal Screening
Intervention:
11 Recruiting Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Biological: IGIV-C 10%;   Biological: IGSC 20%
12 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
13 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:
14 Recruiting Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Condition: Immunologic Deficiency Syndromes
Intervention: Biological: GC5107
15 Recruiting Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Condition: Severe Combined Immunodeficiency Disease, X-linked
Interventions: Genetic: CL20-4i-EF/a-hyc-OPT;   Drug: Busulfan
16 Recruiting A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
Condition: Primary Immunodeficiency
Interventions: Device: Chrono Super PID then Generic Syringe-Gammanorm;   Device: Generic Syringe then Chrono Super PID-Gammanorm
17 Recruiting Diagnostic Immunization With Rabies Vaccine in Patients With PID
Condition: Primary Immunodeficiency
Intervention: Biological: Verorab® (PVRV; Purified Vero Cell Vaccine)
18 Recruiting Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
Condition: Primary Immunodeficiency
Intervention: Biological: IGSC 20%
19 Recruiting Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
Condition: Primary Immunodeficiency (PID)
Intervention: Biological: Gammanorm
20 Recruiting Systematic Search for Primary Immunodeficiency in Adults With Infections
Conditions: Complement Deficiency;   Antibody Deficiency;   Chronic Sinus Infection;   Meningitis, Bacterial;   Pneumonia, Bacterial;   Otitis Media;   Streptococcal Infection;   Neisseria Infections;   Haemophilus Influenza;   Pneumococcal Infections
Intervention: Biological: Immunological diagnosis tests

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.